MALT1 and systemic lupus erythematosus: Our studies indicate that a MALT1 allosteric inhibitor affecting both scaffold and protease activity can be considered as a potential treatment for autoantigen-driven autoimmune pathology due to its effect on TCR- and BCRmediated activation, such as type 1 diabetes and systemic lupus erythematosus.